Nectar Lifesciences Limited — Others, 23-07-2025: Shareholders meeting

Nectar Lifesciences has issued a corrigendum to its upcoming Extraordinary General Meeting (EGM) notice. The board has clarified that the proceeds from a proposed transaction, intended for strategic purposes like debt repayment and new projects, will now explicitly include rewarding shareholders through special dividends and/or equity share buybacks, or a combination of both. This update provides specific details on how the company plans to return value to its investors, offering more clarity on the utilisation of funds from the transaction.